Clinical Trial

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Protocol Amendment History 41 amendments
This ClinicalTrials.gov record has been amended 41 times since 2020-09-25; most recent amendment 2026-06-02.
Status change: Recruiting → Active, Not Recruiting 2025-08-26
Status change: Not Yet Recruiting → Recruiting 2022-01-27
Trial Details
NCT Number NCT04573023
Lead Sponsor JCR Pharmaceuticals Co., Ltd.
Conditions Mucopolysaccharidosis II
Enrollment 86 participants
Start Date 2022-02-14
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-04